An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
Clinical trial NCT03911869 · TERMINATED
Trial details
- NCT number
- NCT03911869
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-30
- Primary completion
- 2022-01-27
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.